Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice L Yu

Showing results (141-150 of 162) with videos related to

Pageof 17
Sort By:
The Lancet. Oncology|May 28, 2017
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trialRajen Mody, Arlene Naranjo, Collin Van Ryn, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|June 18, 2025
Tumor-Associated Glycan Exploits Adenosine Receptor 2A Signaling to Facilitate Immune EvasionJing-Yan Cheng, Hsiu-Hui Tsai, Jung-Tung Hung, et al.
International Journal of Cancer|July 25, 2019
GPER-induced signaling is essential for the survival of breast cancer stem cellsYu-Tzu Chan, Alan C-Y Lai, Ruey-Jen Lin, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 29, 2013
Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancerYen-Lin Huang, Jung-Tung Hung, Sarah K C Cheung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II StudyMorris Kletzel, Howard M Katzenstein, Paul R Haut, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 21, 2023
Targeting of RRM2 suppresses DNA damage response and activates apoptosis in atypical teratoid rhabdoid tumorLe Hien Giang, Kuo-Sheng Wu, Wei-Chung Lee, et al.
Frontiers in Oncology|April 21, 2022
Genomic and Molecular Signatures of Successful Patient-Derived Xenografts for Oral Cavity Squamous Cell CarcinomaWei-Chen Yen, Ian Yi-Feng Chang, Kai-Ping Chang, et al.
Frontiers in Immunology|July 4, 2018
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
Frontiers in Immunology|July 27, 2018
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
The Lancet. Oncology|July 30, 2013
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trialSusan G Kreissman, Robert C Seeger, Katherine K Matthay, et al.
Pageof 17

Showing results (141-150 of 162) with videos related to

Sort By:
Pageof 17
The Lancet. Oncology|May 28, 2017
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trialRajen Mody, Arlene Naranjo, Collin Van Ryn, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|June 18, 2025
Tumor-Associated Glycan Exploits Adenosine Receptor 2A Signaling to Facilitate Immune EvasionJing-Yan Cheng, Hsiu-Hui Tsai, Jung-Tung Hung, et al.
International Journal of Cancer|July 25, 2019
GPER-induced signaling is essential for the survival of breast cancer stem cellsYu-Tzu Chan, Alan C-Y Lai, Ruey-Jen Lin, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 29, 2013
Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancerYen-Lin Huang, Jung-Tung Hung, Sarah K C Cheung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II StudyMorris Kletzel, Howard M Katzenstein, Paul R Haut, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 21, 2023
Targeting of RRM2 suppresses DNA damage response and activates apoptosis in atypical teratoid rhabdoid tumorLe Hien Giang, Kuo-Sheng Wu, Wei-Chung Lee, et al.
Frontiers in Oncology|April 21, 2022
Genomic and Molecular Signatures of Successful Patient-Derived Xenografts for Oral Cavity Squamous Cell CarcinomaWei-Chen Yen, Ian Yi-Feng Chang, Kai-Ping Chang, et al.
Frontiers in Immunology|July 4, 2018
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
Frontiers in Immunology|July 27, 2018
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
The Lancet. Oncology|July 30, 2013
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trialSusan G Kreissman, Robert C Seeger, Katherine K Matthay, et al.
Pageof 17